Neurocrine Biosciences, Inc. P/E Ratio 2009–2025
Neurocrine Biosciences, Inc. reported 30.37 of price-to-earnings ratio for fiscal 2025. That was 26.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +31.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.37 | -26.8% |
| FY 2024 | 41.49 | -22.2% |
| FY 2023 | 53.34 | -30.3% |
| FY 2022 | 76.56 | -17.3% |
| FY 2021 | 92.58 | +301.8% |
| FY 2020 | 23.04 | -91.6% |
| FY 2019 | 275.62 | -15.1% |
| FY 2018 | 324.59 | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | 93.50 | +637.0% |
| FY 2011 | 12.69 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Neurocrine Biosciences, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open NBIX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Neurocrine Biosciences, Inc. reported 30.37 of price-to-earnings ratio for fiscal 2025. That was 26.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +31.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Neurocrine Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s price-to-earnings ratio?
Neurocrine Biosciences, Inc. (NBIX) reported price-to-earnings ratio of 30.37 for fiscal year 2025, per its SEC filings.
How has Neurocrine Biosciences, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, NBIX's price-to-earnings ratio grew at roughly 5.6% per year (compound annual rate), from 12.69 to 30.37.
Where does this data come from?
Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More NBIX financial history
Full NBIX fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →